STOCK TITAN

Inhibrx Biosciences (INBX) president receives 50K stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. reported that President David Matly received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $129.06 per share and expire on April 24, 2036.

According to the vesting terms, 25% of the options become exercisable on April 24, 2027, with the remaining shares vesting in equal monthly installments over the next 36 months, subject to his continuous service with the company. Following this award, he holds 50,000 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Matly David
Role President
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 50,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Stock options granted 50,000 options Grant of stock options to President David Matly
Exercise price $129.06 per share Exercise price for granted stock options
Expiration date April 24, 2036 Option term ending on expiration date
Initial vesting tranche 25% of 50,000 options First vesting on April 24, 2027
Remaining vesting period 36 monthly installments Balance vests monthly after April 24, 2027
Options held after grant 50,000 options Total stock options held directly following transaction
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price set at 129.0600 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date listed as 2036-04-24 for the option"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title identified as Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
vesting financial
"balance to vest and become exercisable in equal successive monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Matly David

(Last)(First)(Middle)
C/O INHIBRX BIOSCIENCES, INC.
11025 NORTH TORREY PINES ROAD, SUITE 140

(Street)
LA JOLLA CALIFORNIA 92037

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Inhibrx Biosciences, Inc. [ INBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$129.0604/24/2026A50,000 (1)04/24/2036Common Stock50,000$050,000D
Explanation of Responses:
1. Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on April 24, 2027, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Remarks:
/s/ Kelly Deck, as attorney-in-fact for David Matly04/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Inhibrx Biosciences (INBX) disclose for David Matly?

Inhibrx Biosciences disclosed that President David Matly received a grant of 50,000 stock options. These options give him the right to buy common shares at a fixed $129.06 exercise price, providing equity-based compensation tied to the company’s future share performance.

What is the exercise price and term of David Matly’s new INBX stock options?

The granted options carry an exercise price of $129.06 per share and expire on April 24, 2036. This long-dated term allows Matly to potentially exercise the options over roughly a decade, depending on market conditions and his continued service.

How do the Inhibrx (INBX) stock options granted to David Matly vest over time?

The options vest gradually. 25% of the 50,000 options become exercisable on April 24, 2027. The remaining 75% vest in equal monthly installments over the following 36 months, aligning long-term incentives with Matly’s continued employment.

What service conditions apply to David Matly’s INBX stock option grant?

Vesting is conditioned on Matly’s continuous service with Inhibrx. He must remain employed through each vesting date for the related portion of his 50,000 options to become exercisable, reinforcing long-term retention and alignment with the company’s performance goals.

How many Inhibrx stock options does David Matly hold after this Form 4 filing?

Following this transaction, President David Matly holds 50,000 stock options directly. All of these options relate to this new grant and will become exercisable over time as they vest under the disclosed schedule, subject to his ongoing service with the company.